UAE Diabetes Drugs Market Analysis

UAE Diabetes Drugs Market Analysis


$ 3999

The UAE diabetes drugs market size was valued at $308.97 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.1% from 2022 to 2030 and will reach $535 Mn in 2030. The market is segmented by drug type, application, and distribution channel. The UAE diabetes drug market will grow as the UAE government's initiatives to address the diabetes epidemic. The key market players are Neopharma (UAE), Julphar (Gulf Pharmaceutical Industries), Boehringer Ingelheim, and others.

ID: IN10AEPH009 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Chandani Patel

Buy Now

UAE Diabetes Drugs Market Executive Summary

The UAE diabetes drugs market size was valued at $308.97 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.1% from 2022 to 2030 and will reach $535 Mn in 2030.  The United Arab Emirates (UAE) has been investing significantly in healthcare, with the aim of providing high-quality healthcare services to its citizens and residents. According to the World Health Organization (WHO), the UAE's total healthcare expenditure was estimated at 4.7% of its gross domestic product (GDP) in 2019. In 2019, the UAE's total healthcare expenditure was around $18 Bn. The government is the largest spender on healthcare in the UAE, accounting for approximately 73% of the total healthcare expenditure. The remaining 27% is spent by the private sector. The UAE's healthcare expenditure has been steadily increasing in recent years, reflecting the government's commitment to improving the healthcare system. The WHO reports that between 2010 and 2019, the UAE's healthcare expenditure increased by 56%. The government has also implemented various initiatives to improve healthcare access and affordability, such as providing free or subsidized healthcare to Emirati citizens and investing in telemedicine and digital health.

According to the International Diabetes Federation's Diabetes Atlas 2021, the prevalence of diabetes in the United Arab Emirates (UAE) in adults aged 20-79 years was 17.9% in 2021. This means that approximately 1.2 Mn adults in the UAE have diabetes. IDF estimates that the number of people with diabetes in the UAE is expected to increase to 2.05 Mn by 2045, representing a 72.2% increase from the 2021 estimates. The high prevalence of diabetes in the UAE is attributed to various factors such as a sedentary lifestyle, unhealthy diet, high rates of obesity, genetic factors, and an aging population. The government of the UAE has implemented various measures to address the problem, including increasing awareness, promoting healthy lifestyles, and providing free screening and treatment for diabetes. The high prevalence of diabetes in the UAE has a significant impact on the diabetes drugs market in the country. With such a large number of people affected by the disease, there is a high demand for diabetes drugs and related products.

The market for diabetes drugs in the UAE is growing, and it is expected to continue to grow in the coming years. Additionally, the growing adoption of advanced diabetes treatments such as insulin pumps, continuous glucose monitoring systems, and smart insulin pens is also contributing to the growth of the diabetes drugs market in the UAE.  Increasing diabetes incidence in the UAE is driving the demand for diabetes drugs, and the market is expected to continue to grow in the coming years. The UAE government's initiatives to address the diabetes epidemic and the growing adoption of advanced diabetes treatments are expected to further boost the growth of the diabetes drugs market in the country.

uae diabetes drugs market

Market Dynamics

Market Growth Drivers Analysis

The diabetes drugs market in the UAE is driven by several factors. One of the key drivers is the high prevalence of diabetes in the country, which creates a high demand for diabetes drugs and related products. The UAE has one of the highest rates of diabetes in the world, with around 1.2 Mn adults estimated to have the disease. This has resulted in a significant market for diabetes drugs, as patients require medication to manage their condition.

Moreover, the UAE government's initiatives to address the diabetes epidemic. The UAE government has implemented various measures to increase awareness about diabetes and promote healthy lifestyles, including free screening and treatment for diabetes. These initiatives have led to increased demand for diabetes drugs as more people are diagnosed with the disease and require treatment.

In addition, the growing adoption of advanced diabetes treatments such as insulin pumps, continuous glucose monitoring systems, and smart insulin pens is driving the growth of the diabetes drug market in the UAE. Patients are increasingly opting for these advanced treatments, which offer improved accuracy and convenience compared to traditional methods.

Market Restraints

One of the major restraints is the high cost of diabetes drugs, which may limit access for some patients. In addition, the availability of cheaper generic alternatives could also pose a challenge for companies operating in the diabetes drugs market.

Competitive Landscape

Key Players

  • Neopharma (UAE)
  • Julphar (Gulf Pharmaceutical Industries)
  • Boehringer Ingelheim
  • Sanofi
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • AstraZeneca
  • Johnson & Johnson
  • Bayer Pharmaceuticals
  • Novo Nordisk
  • Merck
  • Novartis
  • GlaxoSmithKline

Notable deals

January 2021: Julphar announced that it had entered into a partnership with the Abu Dhabi Stem Cell Center (ADSCC) to develop stem cell-based therapies for diabetes and other chronic diseases. The partnership aims to leverage Julphar's expertise in drug development and ADSCC's stem cell research capabilities to develop new treatments for diabetes.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The UAE has a robust regulatory framework for pharmaceutical products, including diabetes drugs. The Ministry of Health and Prevention (MoHAP) is the primary regulatory body responsible for ensuring the safety, efficacy, and quality of pharmaceutical products in the UAE.  All pharmaceutical products, including diabetes drugs, must be registered with the MoHAP before they can be sold in the UAE. The registration process involves a thorough review of the product's safety and efficacy data, as well as its manufacturing processes.

In addition, the MoHAP has established guidelines for the import and distribution of pharmaceutical products, including diabetes drugs. These guidelines outline the requirements for the storage, transport, and handling of pharmaceutical products, to ensure that they maintain their quality and efficacy throughout the supply chain. In the UAE, the government provides healthcare coverage to its citizens and residents through the mandatory health insurance scheme. Under this scheme, individuals and employers are required to purchase health insurance coverage for themselves and their employees.

Diabetes drugs are covered by health insurance in the UAE, but the coverage and reimbursement rates may vary depending on the type of insurance plan and the specific drugs prescribed. In general, health insurance plans in the UAE cover the cost of diabetes drugs as part of the overall treatment for diabetes.

 

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Drugs Market Segmentation

By Drug Type (Revenue, USD Bn):

The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :

  • Injectable Drugs
    • Insulin Based Injectables
    • Non-insulin Based Injectables
      • Exenatide (Byetta)
      • Dulaglutide (Trulicity)
      • Semaglutide (Ozempic, Wegovy)
      • Liraglutide (`Saxenda, Victoza)
      • Lixisenatide (Adlyxin)
      • Pramlintide (Symlin)
      • Tirzepatide (Mounjaro)
      • Albiglutide (Tanzeum)
  • Oral Drugs
    • Biguanides - Metformin (Glucophage and Glucophase XR)
    • Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
    • Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
    • Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
    • Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
    • Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
    • Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
    • Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
    • Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
    • Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
    • Others (Fixed Dose Combination Drugs)

By Application (Revenue, USD Bn):

Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.

  • Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
  • Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
  • Other diabetes types

By Distribution Channel (Revenue, USD Bn):

Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 17 March 2023
Updated by: Keta Vora

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up